The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers

MMC van der Lee, PG Groothuis, R Ubink… - Molecular cancer …, 2015 - AACR
SYD985 is a HER2-targeting antibody–drug conjugate (ADC) based on trastuzumab and vc-
seco-DUBA, a cleavable linker-duocarmycin payload. To evaluate the therapeutic potential …

[HTML][HTML] BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

MJ van Helden, SA Zwarthoff, RJ Arends… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Preclinical studies have firmly established the CD47-signal-regulatory protein
(SIRP) α axis as a myeloid immune checkpoint in cancer, and this is corroborated by …

Preclinical profile of BYON3521 predicts an effective and safe MET antibody–drug conjugate

PG Groothuis, DCH Jacobs, IAT Hermens… - Molecular Cancer …, 2023 - AACR
MET, the cell-surface receptor for the hepatocyte growth factor/scatter factor, which is widely
overexpressed in various solid cancer types, is an attractive target for the development of …

1160 Phosphonate-antibody-drug conjugates: a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell …

MJ van Helden, RC Elgersma, DWJ van Kuppeveld… - 2023 - jitc.bmj.com
Background Gamma delta (γδ) T cells are cytotoxic effector cells that can recognize and kill
tumor cells in a major histocompatibility complex (MHC)-independent fashion. Their …